Table 1 Baseline demographics and clinical characteristics
Monotherapy cohort (n = 26) | Combination cohort (n = 42) | |
|---|---|---|
Sex, n (%) | ||
Male | 16 (61.5) | 26 (61.9) |
Female | 10 (38.5) | 16 (38.1) |
Age (years) | ||
Median (range) | 61.5 (44,75) | 54.0 (32, 76) |
Race, n (%) | ||
Asian | 17 (65.4) | 36 (85.7) |
Hispanic | 1 (3.8) | 0 |
White | 8 (30.8) | 6 (14.3) |
ECOG, n (%) | ||
0 | 11 (42.3) | 13 (31.0) |
1 | 15 (57.7) | 29 (69.0) |
Metastases, n (%) | ||
Yes | 26 (100) | 42 (100) |
Metastases sites, n (%) | ||
Liver | 17 (65.4) | 32 (76.2) |
Lung | 12 (46.0) | 18 (42.9) |
Bone | 6 (23.1) | 2 (4.8) |
Stage at study entry, n (%) | ||
IV | 26 (100) | 42 (100) |
Primary tumor location, n (%) | ||
Left colon | 13 (50.0) | 15 (35.7) |
Right colon | 5 (19.2) | 12 (28.6) |
Rectum | 8 (30.8) | 15 (35.7) |
Number of prior systematic treatment | ||
Median (range) | 3 (1, 10) | 3 (1, 6) |
≥2, n (%) | 24 (92.3) | 36 (85.7) |
≥3, n (%) | 15 (57.7) | 25 (59.5) |
Prior systematic anti-tumor therapy | ||
Fluoropyrimidine/Oxaliplatin/Irinotecan | 26 (100.0)/26 (100.0)/22 (84.6) | 41 (97.6)/42 (100.0)/38 (90.5) |
Anti-VEGF therapy | 23 (88.5) | 39 (92.9) |
Regorafenib and/or trifluridine/tipiracil and/or Fruquintinib | 4 (15.4) | 11 (26.2) |
